RE:RE:Thoughts on Earnings ahead?Hey,
If you go read page 18 of the last MD&A, its states that carried quartely losses from its discontinued ops which include RXi and VPROS is $467k or $850k after tax
The results of the entities that were classified as discontinued operations in the periods are presented below: Three months ended September 30 Nine months ended (Unaudited) September 30 2023 2022 2023 2022 Revenue $ 1,904 $ 14,674 Expenses 2,375 $ 9,302 Impairment Operating loss 15,282 11,272 - (471) 4,044 - $ 42,762 44,480 33,286 Finance costs (4,652) Other income Loss before tax from discontinuing operations 6 - (465) (154) (2,824) (1,970) (75) 14 (35,004) (189) (6,579) Tax (expense)/recovery (385) (7,630) (2,031) 417 (1,351) Gain on sale of Benchmark’s business Loss after tax for the period from discontinuing operations - - 190 (41,772) 426 - $ (850) Loss per share from discontinuing operations $ (7,213) $ (3,192) $ (41,346) $ (0.00) EBITDA and Adjusted EBITDA2 $ (0.02) $ (0.01) $ (0.14) EBITDA for the three and nine months ended September 30, 2023, and 2022, was a loss of $1,312 and $7,702, compared to a loss of $11,705 and $53,872 for the same periods in the prior year.